Table 2: Combined treatment with antiviral therapy and rituximab in MC patients: review of the literature.

Author PatientsMain indicationRegimenTherapy
outcome
(CR/PR/NR)
AEs

Saadoun et al., 2008 [22]16Refractory MCST
(RTX 375 mg/sqm × 4
Peg IFNα2b+ + RBV++ after a month)
(10/6/1)
Terrier et al., 2009 [23]20Severe MCST
(RTX 375 mg/sqm × 4 or 1 gr × 2
Peg IFNα2b+ + RBV++ after a month)
(16/3/1)4°°
Dammacco et al., 2010 [24]22MC
(naïve patients)
CT
(RTX 375 mg/sqm × 4 weekly + two 5 monthly inf. + Peg IFNα2b+ or α2a+++ + RBV++)
(12/5/5)3°°°
Saadoun et al., 2010 [25]38MC
(unselected)
ST
(RTX 375 mg/sqm × 4 or 1 gr × 2
Peg IFNα2b+ or α2a+++ + RBV++ after a month)
(28/9/1)5°°+
Ignatova et al., 2014 [26]6Severe MCST
(RTX n.d. dose
Peg IFNα + RBV++ after a month)
(n.d./n.d./n.d.)n.d.

MC: mixed cryoglobulinemia; ST: sequential treatment; CT: combined treatment; CR: complete response, PR: partial response, NR: no response; AEs: adverse events (requiring antiviral treatment interruption); n.d.: not determined.
+1.5 mcg/kg weekly; ++weight-based; +++180 mcg weekly.
°One worsening of peripheral neuropathy case and 1 flare of psoriasis case.
°°Two hematologic toxicity cases; 1 flare of psoriasis case; 1 hepatocarcinoma case.
°°°One severe anemia case; 2 grade 4 neutropenia cases.
°°+Two hematologic toxicity cases; 1 depression case; 1 flare of psoriasis cases; 1 neuropathy case.